Io­n­is flash­es new An­gel­man syn­drome da­ta, will pur­sue Phase 3 tri­al next year

Io­n­is on Mon­day re­vealed new six-month da­ta from its An­gel­man syn­drome pro­gram, pre­sent­ing Phase 1/2a re­sults from a pooled group of pa­tients tak­ing three dif­fer­ent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER